This study presents genetic evidence highlighting the anti-inflammatory properties of SGLT2 inhibitors and their positive role in lowering the risk of heart failure. CXCL10 was identified as a potential mediator, introducing a novel pathway for heart failure treatment. This evidence concerns the gene SLC5A2 and heart failure.